Cai Jingjing, Yang Guangxia, Zhang Xuemei, Liu Linlin, Yan Mei
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China.
Zhongguo Fei Ai Za Zhi. 2023 Sep 20;26(9):717-720. doi: 10.3779/j.issn.1009-3419.2023.102.32.
Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induced thrombocytopenia is a rare adverse event.We report one case of thrombocytopenia induced by ICIs and review the literature on thrombocytopenia associated with ICIs and discuss the clinical features, possible mechanisms, and optimal treatment. .
免疫检查点抑制剂（ICIs）在肺癌治疗中显示出独特优势，使肺癌治疗进入免疫治疗时代，但ICIs也会产生不良反应，且免疫诱导的血液学毒性发生率不高。免疫治疗诱导的血小板减少是一种罕见的不良事件。我们报告1例由ICIs诱导的血小板减少病例，并复习与ICIs相关的血小板减少的文献，探讨其临床特征、可能机制及最佳治疗方法。
